Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyDavid T Yeung, Timothy P. Hughes, Cecily Forsyth et al.|Blood|2024Cited by 24
Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle StudyDavid T Yeung, On Behalf of the ALLG, Andrew Grigg et al.|Blood|2018Cited by 8
Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle StudyDavid T Yeung, On Behalf of the ALLG, Naranie Shanmuganathan et al.|Blood|2019Cited by 7
Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CMLDavid T Yeung, Timothy P. Hughes, Naranie Shanmuganathan et al.|Blood|2022Cited by 4
Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct StudyDavid T Yeung, On Behalf of the ALLG, Andrew Grigg et al.|Blood|2019Cited by 3